Interferon-α therapy for individuals with normal serum alanine aminotransferase levels before treatmemt

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 1, 1997, Pages 58-61

  Orito, Etsuro ^a   Mizokami, Masashi ^a   Suzuki, Kaoru ^a   Ohba, Ken Ichi ^a   Ohno, Tomoyoshi ^a   Mizuno, Makoto ^b   Iijima, Yoshihiko ^b   Saito, Hiroshi ^c   Nemoto, Akira ^c   Nukuta, Nobuo ^d  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c Municipal Hospital of Nagoya City   (Japan)

^d Department of Urology   (Japan)

Author keywords

bDNA; Chronic hepatitis C; HCV RNA; Hepatitis C virus genotype 2; IFN therapy; Normal ALT level

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 8044252804     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00347.x     Document Type: Article

References (16)

1. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alfa therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
2. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-83.
3. Tsubota A, Chayama K, Ikeda K et al. Factors predictive response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
4. Orito E, Mizokami M, Nakano T et al. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-α therapy in Japanese patients with chronic hepatitis C. J. Med. Virol 1994; 44: 410-14.
5. Alberti A, Morsica G, Chemello L et al. Hepatitis C viremia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-8.
6. Martinot-Peignoux M, Marcellin P, Gournay J et al. Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors. J. Hepatol. 1994; 20: 676-8.
7. Naito M, Hayashi N, Hagiwara H et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19: 871-5.
8. Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
9. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
10. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
11. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: Multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
12. Lau JYN, Davis GL, Orito E, Qian KP, Mizokami M. Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. J. Hepatol. 1993; 17: 253-7.
13. Orito E, Mizokami M, Mizoguchi N et al. Hepatitis C virus serotype II responds more favorably to interferon-α therapy. J. Hepatol. 1994; 21: 130-2.
14. Collins ML, Zayati C, Detmer JJ et al. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal. Biochem. 1995; 226: 120-9.
15. Lau JYN, Simmonds P, Urdea MS. Implications of variations of 'conserved' regions of hepatitis C virus genome. Lancet 1995; 346: 425-6.
16. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.